Metastatic pancreatic cancer: a new standardised dose-reduction regimen?
Authors:
- 16 August 2024
- journal article
- editorial
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 9 (10) , 898-900
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trialThe Lancet Gastroenterology & Hepatology, 2024
- NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trialThe Lancet, 2023
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic CancerJournal of Clinical Oncology, 2009